The COVID-19 (Coronavirus Disease 2019) broke out in the late of 2019. On January 23 in Wuhan, and later in all other cities of the country, there were taken measures to control the spread of the virus through quarantine measures. This article focused on East China and attempted to assess comprehensively the environmental impact of the COVID-19 outbreak. This study analyzed satellite observational data of sulfur dioxide (SO 2), nitrogen dioxide (NO 2), carbon monoxide (CO) and aerosol optical depth (AOD) in the period before the outbreak of the epidemic and during the implementation of preventive measures and control of COVID-19, as well as compared it with the data obtained in the same period of 2019. The results of the analysis showed that the COVID-19 lockdown improved air quality in the short term, but as soon as coal consumption at power plants and refineries returned to normal levels due to the resumption of their work, pollution levels returned to their previous level. The levels of CO and NO 2 showed the most significant decrease (20 and 30%), since they were mainly associated with a decrease in economic growth and transport restrictions that led to a change in energy consumption and a reduction in emissions. This study can complement the scientific community and environmental protection policy makers, not only to assess the impact of outbreak on air quality, but also for its effectiveness as a simple alternative program of action to improve air quality.

PURPOSE Camrelizumab is an antibody against programmed death protein 1. We assessed the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, in patients with advanced cervical cancer. METHODS This multicenter, open-label, single-arm, phase II study enrolled patients with advanced cervical cancer who progressed after at least one line of systemic therapy. Patients received camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day. The primary end point was objective response rate (ORR) assessed by investigators per RECIST version 1.1. Key secondary end points were progression-free survival (PFS), overall survival (OS), duration of response, and safety. RESULTS Forty-five patients were enrolled and received treatment. Median age was 51.0 years (range, 33-67 years), and 57.8% of patients had previously received two or more lines of chemotherapy for recurrent or metastatic disease. Ten patients (22.2%) had received bevacizumab. Median follow-up was 11.3 months (range, 1.0-15.5 months). ORR was 55.6% (95% CI, 40.0% to 70.4%), with two complete and 23 partial responses. Median PFS was 8.8 months (95% CI, 5.6 months to not estimable). Median duration of response and median OS were not reached. Treatment-related grade 3 or 4 adverse events (AEs) occurred in 71.1% of patients, and the most common AEs were hypertension (24.4%), anemia (20.0%), and fatigue (15.6%). The most common potential immune-related AEs included grade 1-2 hypothyroidism (22.2%) and reactive cutaneous capillary endothelial proliferation (8.9%). CONCLUSION Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.

No abstract

No abstract

No abstract